Does a Low Cost for Clinics Mean More Underinsured Patients Are Able to Choose a Hormonal IUD? One Study in Utah Sought to Find Out

At the beginning of this year, an estimated 7.7 million women of reproductive age (15-44) in the United States were uninsured, with 2 million of these women living below the federal poverty level. As the ongoing novel coronavirus pandemic has led to historic numbers of unemployment claims, it is estimated that millions more have lost their employer-provided health insurance. More uninsured people mean more people paying out of their own pockets for birth control, which can be prohibitively expensive.  In the case of long-acting reversible contraceptive (LARC) methods, such as the hormonal intrauterine device (IUD), out of pocket costs can exceed $1,000.

At Medicines360, our mission is to remove cost as a barrier to health by developing and providing affordable women’s health products.  Our ongoing impact measurement initiatives seek to understand to what extent the price of hormonal IUDs impacts a clinic’s ability to offer LARCs to low-income patients, particularly the uninsured or underinsured. We especially want to know whether more patients who desire a hormonal IUD are able to obtain one.

A team led by David Turok and Lauryn Roth at the University of Utah independently studied how the introduction of a low-cost IUD affected uptake of LARC methods. The team retrospectively reviewed electronic medical records from seven family planning clinics in Utah that received federal funds to support family planning access for underserved women (known as Title X grants).

The research team compared uptake of hormonal IUDs and other LARCs before and after the clinics began offering a low-cost IUD in May 2015. Significantly more patients received a hormonal IUD after the introduction of a low-cost product. Insertions of hormonal IUDs increased from approximately 29 per month at the outset of the study period to approximately 43 in the first month after a low-cost product was introduced. There continued to be a steady increase over the following 11 months.

Patients in these clinics also started using other LARCs, such as contraceptive implants and copper IUDs, significantly more in the 11 months after a low-cost product was introduced compared to pre-introduction. Preference for and uptake of use of products in this category may have been influenced by external factors that could not be accounted for including, but not limited to, increased awareness of LARC methods in the community.

The results of this study contribute evidence to our hypothesis that by reducing costs of LARC devices, women may have greater contraceptive access and ability to select a LARC device if desired.  At a time when so many people are likely losing employer-sponsored insurance, Medicines360 is committed to its mission to ensure cost does not stand between a woman and her access to medicines. 

To read more about it, access the full article from the July 2018 issue of Contraception here.

About Medicines360

Located in San Francisco, California, Medicines360 is a global nonprofit pharmaceutical organization with a mission to accelerate the timeline from health innovation to access for all women. Medicines360 is committed to working with healthcare providers, advocacy groups, and patients to deliver innovative and meaningful treatments that help women around the world have greater access to the medicines they need. For more information, visit

Share This

AVIBELA can be made available in the following 88 countries

  1. Algeria
  2. Angola
  3. Bangladesh
  4. Belize
  5. Benin
  6. Bhutan
  7. Botswana
  8. Burkina Faso
  9. Burundi
  10. Cambodia
  11. Cameroon
  12. Cape Verde
  13. Central African Republic
  14. Chad
  15. Comoros
  16. Costa Rica
  17. Cuba
  18. Democratic Republic of the Congo
  19. Djibouti
  20. Dominica
  21. Dominican Republic
  22. Egypt
  23. El Salvador
  24. Equatorial Guinea
  25. Eritrea
  26. Ethiopia
  27. Gabon
  28. Ghana
  29. Grenada
  30. Guatemala
  31. Guinea
  32. Guinea-Bissau
  33. Haiti
  34. Honduras
  35. India
  36. Indonesia
  37. Ivory Coast
  38. Jamaica
  39. Kenya
  40. Lao PDR
  41. Lesotho
  42. Liberia
  43. Libya
  44. Madagascar
  45. Malawi
  46. Malaysia
  47. Maldives
  48. Mali
  49. Mauritania
  50. Mauritius
  51. Mayotte
  52. Morocco
  53. Mozambique
  54. Myanmar
  55. Namibia
  56. Nepal
  57. Nicaragua
  58. Niger
  59. Nigeria
  60. Pakistan
  61. Panama
  62. Papua New Guinea
  63. Philippines
  64. Republic of the Congo
  65. Rwanda
  66. Sao Tome and Principe
  67. Senegal
  68. Seychelles
  69. Sierra Leone
  70. Somalia
  71. South Africa
  72. South Sudan
  73. Sri Lanka
  74. Kitts and Nevis
  75. Lucia
  76. Vincent & the Grenadines
  77. Sudan
  78. Swaziland
  79. Tanzania
  80. Thailand
  81. The Gambia
  82. Timor-Leste
  83. Togo
  84. Tunisia
  85. Uganda
  86. Vietnam
  87. Zambia
  88. Sri Lanka

Tina Raine-Bennett, MD, MPH, FACOG

Chief Executive Officer

Tina Raine-Bennett, MD, MPH, is CEO of Medicines360. Previously, she served as a senior research scientist at the Kaiser Permanente Northern California Division of Research and the research director of the Women’s Health Research Institute. She is a Board-Certified Obstetrician Gynecologist who received her medical training at the University of California, San Diego, and post-graduate residency training and MPH at the University of Washington in Seattle, where she also completed a Robert Wood Johnson Clinical Scholars Fellowship. She was also senior staff physician at Kaiser Permanente and has a special interest in family planning and adolescent reproductive health.

As the director of the Women’s Health Research Institute, Dr. Raine-Bennett focused on expanding research on women’s health within the Division and translating women’s health research into clinical practice and policy within the Ob/Gyn departments in Northern California. She also promoted the involvement of clinicians in research designed to improve the health outcomes and healthcare experiences of women at Kaiser Permanente and women in general.

Prior to Kaiser Permanente, Dr. Raine-Bennett was a professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at University of California, San Francisco (UCSF). She was based at San Francisco General Hospital where she was also the medical director of the New Generation Health Center, a UCSF affiliate site that provides community-based reproductive health services. Dr. Raine-Bennett’s research has focused on contraceptive methods and on elucidating factors that influence contraceptive choice and continuation, and she was principal investigator on NIH grants to assess hormonal contraceptive use predictors and develop interventions to improve contraceptive access.

Her past and current research on emergency contraception has focused on the safety of making emergency contraception more accessible and she conducted a pivotal clinical trial to make emergency contraception available to teens without a prescription. She served on the editorial board of Obstetrics and Gynecology and has over 100 peer-reviewed publications. She was the Treasurer of the Board of Directors for the Society of Family Planning and Society of Family Planning Research Fund. She has also served as an examiner for the American Board of Obstetrics and Gynecology, and on national committees for the American College of Obstetrics and Gynecology and the National Medical Board of Planned Parenthood Federation of America.